The legal status of kratom is under review in Thailand. Options include making kratom available only by prescription, decriminalizing small amounts and total legalization. “There’s never been a single death associated with kratom,” said Pascal Tanguay, who investigated kratom use for the Transnational Institute. “People have been chewing this for thousands of years with no cases of overdose, psychosis, murder, violent crime. Never in all of recorded history.”
Public Health Minister Pradit Sintavanarong confirmed yesterday that the narcotics control committee under the Food and Drug Administration (FDA) has still not reached a decision on whether to remove kratom from the prohibited narcotics list. It could take another two months for the sub-panel, assigned to gather information on the tropical evergreen, to reach its conclusions. (See also: Justice favours legalising krathom and Kratom in Thailand)
The leafy substance khat, grown by many Kenyan farmers, is of economic and cultural significance to many Africans. The UK government has decided, against the advice of its own experts, to treat khat as a class C drug to "protect vulnerable members of our communities". In July, UK Home Secretary Theresa May said khat would be banned "at the earliest possible opportunity" but a ban has yet to be imposed. A team of Kenyan MPs lobby the UK government not to follow suit.
Khat, a stimulant drug, is chewed by around 90,000 people in the east African and Yemeni communities in the UK. But now the Home Office is considering banning the substance. During the last election, pro-ban activists met politicians, offering them community votes. In return, they wanted their support for the ban on khat. Some politicians accepted the offer and supported the mission.
Calls for the herbal high khat to be banned in the UK have been renewed days before a government report into its usage is due to be published. Some members of the British-Somali community have been calling for years for khat to be made illegal. But traders say a ban would not mean an end to khat in the UK as, according to them, smuggled khat is still widely available in Europe and the US, although it is more expensive.
A clash between the home secretary, Theresa May, and her expert drugs advisory group is looming after it decided against banning qat, a mild herbal stimulant, traditionally used in Britain's Somali, Yemeni and Ethiopian communities. The Advisory Council on the Misuse of Drugs said there was insufficient evidence that Qat caused health or wider societal problems to justify a ban in Britain.
A decision by the UK government to ban the stimulant khat later this year is facing fierce resistance in Kenya from those farming the mildly narcotic leaves for export. Local leaders are not happy with the UK's decision to reclassify khat as a class C drug. The local MP, Kubai Kiringo, tells me Kenya could reconsider its ties to Britain if the UK does not drop the ban. "We feel bitter and short-changed. We want the home secretary to revise her decision," he says. (See also: Harmless habit or dangerous drug?)
The Advisory Council on the Misuse of Drugs (ACMD) said there was "insufficient evidence" that khat caused health problems. The stimulant is traditionally used by members of the Somali, Yemeni and Ethiopian communities. It has been outlawed by the US and Canada and in most European countries, most recently by the Netherlands. The review was commissioned by the Home Office. The ACMD said there was "no evidence" khat was directly linked with serious or organised crime. (See also: Chewing over Khat prohibition)
On the basis of the available evidence, the overwhelming majority of Council members consider that khat should not be controlled under the Misuse of Drugs Act 1971. In summary the reason for this is that, save for the issue of liver toxicity, although there may be a correlation or association between the use of khat and various negative social indicators, it is not possible to conclude that there is any causal link.
For forty years the Misuse of Drugs Act 1971 has formed the corner stone of drug policy in Britain. The emergence of new psychoactive substances (‘legal highs’) during the past fifteen years or so has challenged the drug control system. The arrival in 2012 of a new psychoactive substance on the market, on average, every six days raises questions about how best to protect young people from unknown and unsafe drugs. The Government is considering this challenge and we hope this Inquiry report will make a helpful contribution to their deliberations.
The leaves of kratom, a native of Southeast Asia in the coffee family, are used to relieve pain and improve mood as an opiate substitute and stimulant. The herb is also combined with cough syrup to make a popular beverage in Thailand called "4x100." Because of its psychoactive properties, kratom is illegal in Thailand, Australia, Myanmar (Burma) and Malaysia. Thailand is considering legalizing kratom as a safer alternative for meth addicts, and U.S. researchers are studying its potential to help opiate abusers kick the habit without withdrawal side effects.
Norwegian customs officials are calling for increased funding after a surge in the quantity of synthetic cannabis coming into the country - most of it bought on the internet and delivered by post. "The problem is that synthetic cannabis is very much more dangerous than ordinary cannabis," according to the Norwegian Customs Association. "You never know what's in it." (See also: Norway's greens call for state cannabis farms)
New psychoactive drugs (NPDs, new psychoactive substances) enter the market all the time. However, it takes several months to ban these NPDs and immediate action is generally not possible. Several European countries and drug enforcement officers insist on a faster procedure to ban NPDs. Introduction of generic legislation, in which clusters of psychotropic drugs are banned in advance, has been mentioned as a possible solution. Here we discuss the pros and cons of such an approach.